Literature DB >> 679460

Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system ((Biostator).

E J Fogt, L M Dodd, E M Jenning, A H Clemens.   

Abstract

The Glucose-Controlled Insulin Infusion System (Biostator) is a modular, computerized, feedback control system for dynamic control of blood glucose concentrations in diabetics. This on-line glucose analyzer for use with whole blood utilizes a novel enzyme (glucose oxidase)-membrane configuration and an electrochemical cell to measure the H202 generated. The analyzer exhibits both short- and long-range stability, and instrument response and analyte concentration are linearly related over the full range of clinical interest. The response is fast, accurate, and precise, and permits determination of blood glucose within 2 min from the moment the blood leaves the patient. Correlation studies were completed to show the agreement between the Biostator Glucose Analyzer and the FDA's recommended hexokinase/glucose-6-phosphate dehydrogenase procedure on whole blood (e.g., average per cent recovered for 11 concentrations between 250 and 900 mg/liter was: hexokinase, 95.6%, Biostator Analyzer, 95.9%; bias and SDd, respectively, at low, normal, and high glucose values were: 12 and 41 mg/liter at the 500 mg/liter level; 4 and 52 mg/liter at the 1000 mg/liter level, and 4 and 128 mg/liter at the 4000 mg/liter level). No appreciable interference is observed with above-normal concentrations of bilirubin, uric acid, creatinine, sodium salicylate, or dextran. Platelet adhesion, which tends to decrease the useful life of the membrane, has been significantly decreased.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679460

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

Review 1.  Can technological solutions for diabetes replace islet cell function?

Authors:  Justin M Gregory; Daniel J Moore
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

Review 2.  Monitoring for adverse drug reactions.

Authors:  J J Coleman; R E Ferner; S J W Evans
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

3.  Design and in silico evaluation of an intraperitoneal-subcutaneous (IP-SC) artificial pancreas.

Authors:  Justin J Lee; Eyal Dassau; Howard Zisser; Francis J Doyle
Journal:  Comput Chem Eng       Date:  2014-11-05       Impact factor: 3.845

4.  In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting technosphere insulin with zone model predictive control.

Authors:  Justin J Lee; Eyal Dassau; Howard Zisser; Rebecca A Harvey; Lois Jovanovič; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

5.  Optimal control of blood glucose: the diabetic patient or the machine?

Authors:  Larry Brown; Elazer R Edelman
Journal:  Sci Transl Med       Date:  2010-04-14       Impact factor: 17.956

Review 6.  Haemocompatibility of invasive sensors.

Authors:  Y Benmakroha; S Zhang; P Rolfe
Journal:  Med Biol Eng Comput       Date:  1995-11       Impact factor: 2.602

7.  Portable insulin infusion pumps: what is their role in therapy?

Authors:  R P Eaton
Journal:  Drugs       Date:  1982-04       Impact factor: 9.546

Review 8.  Wearable and implantable pancreas substitutes.

Authors:  Leonardo Ricotti; Tareq Assaf; Paolo Dario; Arianna Menciassi
Journal:  J Artif Organs       Date:  2012-09-20       Impact factor: 1.731

Review 9.  A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy.

Authors:  P A Bakhtiani; L M Zhao; J El Youssef; J R Castle; W K Ward
Journal:  Diabetes Obes Metab       Date:  2013-04-21       Impact factor: 6.577

10.  Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects.

Authors:  A E Pontiroli; M Alberetto; A Secchi; G Dossi; I Bosi; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.